Effects of etanercept in patients with the metabolic syndrome.

Archives of Internal Medicine
L Elizabeth BernsteinSteven K Grinspoon

Abstract

Adipose-derived cytokines, including tumor necrosis factor alpha, may contribute to the inflammation that occurs in the metabolic syndrome. We investigated the effects of inhibition of tumor necrosis factor alpha with etanercept in patients with the metabolic syndrome. Fifty-six subjects with the metabolic syndrome were randomized to administration of either etanercept or identical placebo, 50 mg subcutaneously once a week for 4 weeks. The C-reactive protein level was the primary end point. Effects on other inflammatory markers (including fibrinogen, interleukin 6, and adiponectin), insulin sensitivity, lipid levels, and body composition were also determined. Baseline characteristics were similar between the groups. Two subjects dropped out of each group, and etanercept was well tolerated throughout the study. The C-reactive protein levels decreased significantly in the treated compared with the placebo group (-2.4 +/- 0.4 vs 0.5 +/- 0.7 mg/L; P<.001). Adiponectin levels rose significantly in the etanercept group compared with the placebo group (0.8 +/- 0.4 vs -0.3 +/- 0.3 microg/mL; P = .03). Fibrinogen levels decreased (-68 +/- 16 vs -2 +/- 31 mg/dL [-2.0 +/- 0.47 vs -0.06 +/- 0.91 micromol/L]; P = .04) and interleukin 6 leve...Continue Reading

References

Jul 1, 1982·The American Journal of Clinical Nutrition·G A BorkanJ E Silbert
Oct 1, 1994·The Journal of Clinical Investigation·G S HotamisligilB M Spiegelman
Dec 17, 1997·The Journal of Clinical Endocrinology and Metabolism·V Mohamed-AliS W Coppack
Jan 16, 2002·JAMA : the Journal of the American Medical Association·Earl S FordWilliam H Dietz
Sep 13, 2002·Journal of the American College of Cardiology·Fahim AbbasiGerald M Reaven
Dec 4, 2002·JAMA : the Journal of the American Medical Association·Hanna-Maaria LakkaJukka T Salonen
Apr 30, 2003·Expert Opinion on Biological Therapy·Allen P Anandarajah, Christopher T Ritchlin
Jul 5, 2003·The Journal of Clinical Endocrinology and Metabolism·Michio ShimabukuroYuji Matsuzawa
Apr 15, 2004·JAMA : the Journal of the American Medical Association·Tobias PischonEric B Rimm
Jun 8, 2004·The Journal of Clinical Endocrinology and Metabolism·Antonios M XydakisChristie M Ballantyne
Sep 10, 2004·The Journal of Clinical Endocrinology and Metabolism·A N VgontzasG P Chrousos
Sep 29, 2004·Diabetes Care·Earl S FordAli H Mokdad
Nov 25, 2004·American Journal of Physiology. Endocrinology and Metabolism·Bohan WangPaul Trayhurn
Nov 25, 2004·American Journal of Physiology. Endocrinology and Metabolism·Tongjian YouBarbara J Nicklas

❮ Previous
Next ❯

Citations

Jan 15, 2014·Best Practice & Research. Clinical Endocrinology & Metabolism·Kieren J Mather, Ronald B Goldberg
Jan 15, 2014·Drugs·Sarah ChurtonNeil J Korman
Oct 20, 2009·European Journal of Endocrinology·Panayota MitrouGeorge Dimitriadis
Mar 22, 2014·Veterinary Immunology and Immunopathology·Kolapo M Ajuwon
Jun 6, 2013·Mediators of Inflammation·Alexandre FisetteKatherine Cianflone
May 24, 2014·Nature Reviews. Drug Discovery·Marc Y Donath
Sep 10, 2014·Best Practice & Research. Clinical Gastroenterology·Nicolas Lanthier, Isabelle A Leclercq
Feb 13, 2010·Annual Review of Physiology·Jerrold M Olefsky, Christopher K Glass
Apr 22, 2014·Molecular Metabolism·Matthias Blüher
May 10, 2007·Canadian Journal of Physiology and Pharmacology·Kerry B Goralski, Christopher J Sinal
Mar 16, 2013·Current Diabetes Reports·Eric Lontchi-YimagouAndre Pascal Kengne
Mar 22, 2007·American Journal of Physiology. Endocrinology and Metabolism·Janet LoSteven K Grinspoon
Jan 19, 2008·Molecular Endocrinology·Rexford S Ahima, Mitchell A Lazar
Feb 1, 2008·Molecular Medicine·Herbert Tilg, Alexander R Moschen
Nov 15, 2008·Molecular Medicine·Katja RabeUli C Broedl
Oct 31, 2009·Journal of Applied Physiology·Alan R SchwartzPhilip L Smith
Mar 3, 2010·Proceedings of the National Academy of Sciences of the United States of America·Bronwen MartinMark P Mattson
Nov 26, 2010·Clinical Chemistry·Allison B GoldfineSteven E Shoelson
May 1, 2013·Proceedings of the National Academy of Sciences of the United States of America·Myriam AouadiMichael P Czech
Jan 1, 2012·The Review of Diabetic Studies : RDS·Thomas Mandrup-Poulsen
Dec 3, 2013·The Journal of Clinical Investigation·Anthony W Ferrante
Apr 24, 2012·Journal of Nutrition and Metabolism·Faloia EmanuelaBoscaro Marco
May 14, 2008·Current Hypertension Reports·Liza K Phillips, Johannes B Prins
Sep 8, 2012·The Proceedings of the Nutrition Society·Lynda M Williams
Jan 12, 2013·Archivum Immunologiae Et Therapiae Experimentalis·Verena WieserHerbert Tilg
Jun 14, 2013·Journal of Diabetes Research·Yu LiJing Shang
Dec 14, 2011·Immunologic Research·Kitty P CheungJulie M Jameson
Jun 7, 2008·Journal of Biomedical Science·Jin-Ying LuWei-Shiung Yang
Feb 15, 2008·The Journal of Dermatological Treatment·Alice B GottliebFrank Dann
Feb 6, 2008·Expert Opinion on Drug Metabolism & Toxicology·John D Imig
Oct 28, 2014·Expert Opinion on Investigational Drugs·Nathalie EsserAndré J Scheen
Sep 23, 2010·Scandinavian Journal of Rheumatology·J C F van LuijnH G M Leufkens
Jul 6, 2013·Dermatologic Clinics·Thomas Mandrup-Poulsen
Oct 17, 2012·Molecular Aspects of Medicine·Carey N Lumeng
Oct 11, 2012·Journal of Biomedicine & Biotechnology·Sandro M HirabaraRui Curi
Jun 9, 2012·Gastroenterology·Marcelo B S FloresJosé B C Carvalheira
Jun 1, 2010·Annales de dermatologie et de vénéréologie·Thierry Passeron, Serge Boulinguez

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.